Additional Relevant Details - Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS)


- Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat


- No New Safety Signals Compared to Previous Trials of Luvadaxistat